Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Provagin is a vaginal moisturizing gel containing 0.20% sodium hyaluronate, developed by Biolab Sanus Farmacêutica for the treatment of vaginal dryness. Sodium hyaluronate is a naturally occurring polysaccharide that acts as a biologic moisturizing agent. It works by providing local hydration and lubrication to vaginal tissue through its unique water-retention properties, forming a protective film on the vaginal mucosa. The product is indicated for the relief of symptoms such as itching, irritation, and reduced lubrication associated with menopause, postpartum, hormonal contraceptive use, and oncological treatments. It has been evaluated in Phase 3 clinical trials for its hydration efficacy and acceptability in menopausal women.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Provagin.